A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2019
At a glance
- Drugs Cabozantinib (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 03 Jan 2019 Planned End Date changed from 31 Mar 2019 to 30 Sep 2020.
- 03 Jan 2019 Planned primary completion date changed from 31 Mar 2019 to 30 Sep 2020.
- 31 Aug 2018 Biomarkers information updated